Astellas Pharma Inc. and Seattle Genetics Inc. announced data from the first cohort of a pivotal phase II clinical trial known as EV-201 demonstrated the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44% (55/125; 95% Confidence Interval: 35.1-53.2).
As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality.
